Rubius Therapeutics
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Pablo Cagnoni
Employees
213
Country
United States
ISIN
US78116T1034
Listings
0 Comments
Share your thoughts
FAQ
What is Rubius Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Rubius Therapeutics stocks are traded under the ticker 5RT.MU.
How many employees does Rubius Therapeutics have?▼
As of July 19, 2026, the company has 213 employees.
In which sector is Rubius Therapeutics located?▼
Rubius Therapeutics operates in the Technology sector.
When did Rubius Therapeutics complete a stock split?▼
Rubius Therapeutics has not had any recent stock splits.
Where is Rubius Therapeutics headquartered?▼
Rubius Therapeutics is headquartered in Cambridge, United States.